4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide,
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide hydrochloride,
IY5511,
IY5511HCl,
radotinib,
Radotinib,
926037-48-1,
supect,
IY-5511,
Radotinib(IY-5511),
UNII-I284LJY110,
IY5511,
I284LJY110,
4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide,
4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyrazin-2-yl)pyrimidin-2-yl]amino}benzamide,
IY5511HCl,
Radotinib [INN],
Radotinib (IY-5511),
Radotinib; IY-5511;,
GTPL7814,
SCHEMBL3359952,
DTXSID90239069,
AOB87198,
BCP12554,
EX-A1035,
MFCD27956910,
s8134,
ZINC59749972,
AKOS026750428,
AKOS032950010,
DB12323,
IY 5511,
SB11083,
NCGC00390586-01,
4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide,
AK548120,
BC600723,
DA-40474,
KB-146009,
B5846,
FT-0700508,
A13029,
2?,3?,17?-Trihydroxy-7?-6-oxo-5?-androstan,
J-690392,
Anticancer, Il-yang,
radotinib hydrochloride,
radotinib dihydrochloride,
Radotinib?IY-5511),
D01NIR,
IY-GV50205,
4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyrazin-2-yl)pyrimidin-2-yl)amino)benzamide hydrochloride,